Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?
Chanson
P
P
Service d'Endocrinologie et des Maladies de la Reproduction, C.H.U. de Bicêtre et Université Paris XI, Le Kremlin-Bicêtre, France.
D000172:Acromegaly / Q000188:drug therapy* / Q000191:economics / Q000532:radiotherapy; D000236:Adenoma / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D003362:Cost-Benefit Analysis; D006728:Hormones / Q000627:therapeutic use*; D006801:Humans; D015282:Octreotide / Q000627:therapeutic use*; D010456:Peptides, Cyclic / Q000627:therapeutic use*; D010911:Pituitary Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy / Q000473:pathology; D011237:Predictive Value of Tests; D011877:Radionuclide Imaging / Q000379:methods; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000627:therapeutic use
D006728:Hormones; D010456:Peptides, Cyclic; C060347:lanreotide; D013004:Somatostatin; D015282:Octreotide